1. Bharuch agro CDMO contract - The USD 300 million, five-year contract with a leading global agrochemical innovator started commercial dispatches in March 2026, with Q2 FY27 volumes guided higher than Q1. At roughly ₹500 crore annual revenue against company EBITDA of ₹624 crore, and margins above the 20% threshold, this single contract can lift Specialty Chemicals earnings materially this year.
2. CDMO molecule pipeline - Confirmed molecules rose to 25 in Q1 FY27, up from 20 last quarter, with 10+ advanced-stage opportunities carrying ₹1,100 crore peak revenue potential. Management targets 5x CDMO growth by FY27 and \~10x by FY30, with first-year revenues typically reaching 15-20% of peak - the funnel is the engine behind that guide.
3. Gajraula multipurpose plant - Construction is on track for commissioning by end of calendar 2026, with volumes ramping from 2027. This adds the capacity needed to convert the 100+ molecule opportunity funnel into revenue, removing the main bottleneck to CDMO and Fine Chemicals growth.
4. Niacinamide cGMP plant ramp-up - The new 5,000-ton Bharuch plant is already at 50%+ of envisaged volumes, targeting 70% by end of this year. With a $2-3 per kg price premium for cosmetic and food grades over feed grade, and steady-state EBITDA margins of 16-18% once high-grade share reaches 60-70%, mix shift alone can lift Nutrition margins from the current 15%.
5. EU choline anti-dumping tailwind - EU anti-dumping duties on Chinese-origin choline have created a pipeline of orders, with early volumes already booked and delivered in Q2 at better realizations than domestic. Product approvals are underway with at least a dozen customers, and the company has maintained domestic leadership in Vitamin B4 - this is a concrete, tariff-driven share gain.
6. Remidex Pharma acquisition - The ₹16.5 crore acquisition of Remidex Pharma, completed March 30, 2026, adds a WHO-GMP certified premix manufacturing facility in Bengaluru and is already showing traction with Tier-1 human nutrition customers. It moves the company up the value chain from vitamins into finished premixes, a new revenue stream expected to contribute meaningfully from FY27.
7. Acetyls recovery - Chemical Intermediates Q1 FY27 revenue rose 38% YoY with EBITDA up 240% YoY, driven by better realizations in Acetic Anhydride and Ethyl Acetate plus European market share gains. With European plant closures and force majeure events, management expects continued volume gains in Europe this year - a cyclical recovery on top of structural share gains.
8. ₹2,000 crore capex completion - The three-year, ₹2,000 crore capex programme is nearly fully deployed, with FY27 capex guided at ₹400-500 crore, down from the peak. Management expects this to generate roughly ₹3,000 crore of additional revenue on a base of ₹3,000-3,500 crore - the falling capex bill should convert into rising free cash flow as new plants ramp.
9. Lean savings programme - Management targets ₹100 crore of lean savings in FY27, after delivering ₹120+ crore in FY26. Against FY26 EBITDA of ₹624 crore, this is a \~16% earnings uplift that flows straight to the bottom line.